Discontinued — last reported Q4 '23
SOD1 — Research and development:
Biogen SOD1 — Research and development: remained flat by 0.0% to $4.00M in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 5.9%, from $4.25M to $4.00M. Over 2 years (FY 2021 to FY 2023), SOD1 — Research and development: shows an upward trend with a 26.5% CAGR.
Analysis
How to read this metric
An increase indicates intensified development efforts or advancing clinical trial phases, while a decrease may signal project completion, prioritization shifts, or cost-cutting measures.
Detailed definition
This metric represents the direct operating expenses incurred by the company specifically for the research and developme...
Peer comparison
Comparable to R&D spend on specific pipeline assets or clinical-stage programs at other biopharmaceutical companies.
biib_segment_sod1_research_and_developmentHistorical Data
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $10.00M | $17.00M | $16.00M |
| YoY Change | — | +70.0% | -5.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's sod1 — research and development:?
- Biogen (BIIB) reported sod1 — research and development: of $4.00M in Q4 2023.
- How has Biogen's sod1 — research and development: changed year-over-year?
- Biogen's sod1 — research and development: decreased by 5.9% year-over-year, from $4.25M to $4.00M.
- What is the long-term trend for Biogen's sod1 — research and development:?
- Over 2 years (2021 to 2023), Biogen's sod1 — research and development: has grown at a 26.5% compound annual growth rate (CAGR), from $10.00M to $16.00M.
- What does sod1 — research and development: mean?
- The total costs spent on researching and developing the SOD1 drug candidate.